Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

ABSTRACT: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy. However, many patients with advanced NSCLC who have mutated EGFR do not respond to first-line EGFR-TKI treatment and still have shorter PFS.The aim of this study was to identify genetic variants associated with PFS among patients with lung adenocarcinoma who were treated with first-line EGFR-TKIs.A genome-wide association study on PFS was performed in never-smoking women diagnosed with lung adenocarcinoma and who were treated with first-line EGFR-TKIs (n?=?128). Significant single-nucleotide polymorphisms (SNPs) were selected for follow-up association analysis (n?=?198) and for replication assay in another independent cohort (n?=?153).We identified SNPs at 4q12 associated with PFS at genome-wide significance (P?

SUBMITTER: Chang IS 

PROVIDER: S-EPMC5363976 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature